FKBPs and the Akt/mTOR pathway

Cell Cycle

Volumn 12, Issue 15, 2013, Pages 2366-2370

  Hausch, Felix ^a   Kozany, Christian ^a   Theodoropoulou, Marily ^a   Fabian, Anne Katrin ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Akt; FK506 binding protein; FKBP; MTOR; PKB; Rapamycin

Indexed keywords

FK 506 BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN;

CRYSTAL STRUCTURE; CRYSTALLIZATION; GENETIC MANIPULATION; INTRACELLULAR SIGNALING; MAMMAL CELL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; REVIEW; TETRATRICOPEPTIDE REPEAT;

MAMMALIA;

AKT; FK506 BINDING PROTEIN; FKBP; MTOR; PKB; RAPAMYCIN;

ANIMALS; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TACROLIMUS BINDING PROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84881521734     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25508     Document Type: Review

References (40)

1. Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev 2013; 23:53-62; PMID:23317514; http://dx.doi. org/10.1016/j.gde.2012.12.005
2. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-93; PMID:22500797; http://dx.doi.org/10.1016/j. cell.2012.03.017
3. Gaali S, Gopalakrishnan R, Wang Y, Kozany C, Hausch F. The chemical biology of immunophilin ligands. Curr Med Chem 2011; 18:5355-79; PMID:22087830; http://dx.doi. org/10.2174/092986711798194342
4. Wang X, Proud CG. mTORC1 signaling: what we still don't know. J Mol Cell Biol 2011; 3:206-20; PMID:21138990; http://dx.doi.org/10.1093/jmcb/mjq038
5. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature 2013; 497:217-23; PMID:23636326; http://dx.doi.org/10.1038/nature12122
6. Oshiro N, Yoshino K, Hidayat S, Tokunaga C, Hara K, Eguchi S, et al. Dissociation of raptor from mTOR is a mechanism of rapamycininduced inhibition of mTOR function. Genes Cells 2004; 9:359-66; PMID:15066126; http://dx.doi. org/10.1111/j.1356-9597.2004.00727.x
7. Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 2010; 38:768-74; PMID:20542007; http://dx.doi. org/10.1016/j.molcel.2010.05.017
8. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22:159-68; PMID:16603397; http://dx.doi. org/10.1016/j.molcel.2006.03.029
9. Takai H, Xie Y, de Lange T, Pavletich NP. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. Genes Dev 2010; 24:2019-30; PMID:20801936; http://dx.doi. org/10.1101/gad.1956410
10. Choo AY, Yoon S-O, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 2008; 105:17414-9; PMID:18955708; http://dx.doi. org/10.1073/pnas.0809136105
11. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7:e38; PMID:19209957; http://dx.doi.org/10.1371/journal. pbio.1000038
12. García-Martínez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM, et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009; 421:29-42; PMID:19402821; http://dx.doi.org/10.1042/BJ20090489
13. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284:8023-32; PMID:19150980; http://dx.doi.org/10.1074/jbc. M900301200
14. Kozany C, März A, Kress C, Hausch F. Fluorescent probes to characterise FK506-binding proteins. Chembiochem 2009; 10:1402-10; PMID:19418507; http://dx.doi.org/10.1002/cbic.200800806
15. März AM, Fabian A-K, Kozany C, Bracher A, Hausch F. Large FK506-binding proteins shape the pharmacology of rapamycin. Mol Cell Biol 2013; 33:1357-67; PMID:23358420; http://dx.doi.org/10.1128/MCB.00678-12
16. Weiwad M, Edlich F, Kilka S, Erdmann F, Jarczowski F, Dorn M, et al. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. Biochemistry 2006; 45:15776-84; PMID:17176100; http://dx.doi. org/10.1021/bi061616p
17. Delgoffe GM, Kole TP, Cotter RJ, Powell JD. Enhanced interaction between Hsp90 and raptor regulates mTOR signaling upon T cell activation. Mol Immunol 2009; 46:2694-8; PMID:19586661; http://dx.doi.org/10.1016/j.molimm.2009.05.185
18. Bracher A, Kozany C, Thost AK, Hausch F. Structural characterization of the PPIase domain of FKBP51, a cochaperone of human Hsp90. Acta Crystallogr D Biol Crystallogr 2011; 67:549-59; PMID:21636895; http://dx.doi.org/10.1107/ S0907444911013862
19. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 2004; 101:6062-7; PMID:15075390; http://dx.doi.org/10.1073/pnas. 0400782101
20. Wang T, Donahoe PK. The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors. Front Biosci 2004; 9:619-31; PMID:14766396; http://dx.doi.org/10.2741/1095
21. Mathea S, Li S, Schierhorn A, Jahreis G, Schiene-Fischer C. Suppression of EGFR autophosphorylation by FKBP12. Biochemistry 2011; 50:10844-50; PMID:22103444; http://dx.doi. org/10.1021/bi2013855
22. Chelu MG, Danila CI, Gilman CP, Hamilton SL. Regulation of ryanodine receptors by FK506 binding proteins. Trends Cardiovasc Med 2004; 14:227-34; PMID:15451514; http://dx.doi.org/10.1016/j. tcm.2004.06.003
23. Ahearn IM, Tsai FD, Court H, Zhou M, Jennings BC, Ahmed M, et al. FKBP12 binds to acylated H-ras and promotes depalmitoylation. Mol Cell 2011; 41:173-85; PMID:21255728; http://dx.doi. org/10.1016/j.molcel.2011.01.001
24. Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y, et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 2007; 318:977-80; PMID:17991864; http://dx.doi.org/10.1126/science.1147379
25. Dunlop EA, Dodd KM, Seymour LA, Tee AR. Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein-protein interactions for substrate recognition. Cell Signal 2009; 21:1073-84; PMID:19272448; http://dx.doi. org/10.1016/j.cellsig.2009.02.024
26. Ma D, Bai X, Guo S, Jiang Y. The switch I region of Rheb is critical for its interaction with FKBP38. J Biol Chem 2008; 283:25963-70; PMID:18658153; http://dx.doi.org/10.1074/jbc.M802356200
27. Peng L, Liang D, Tong W, Li J, Yuan Z. Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J Biol Chem 2010; 285:20870-81; PMID:20439463; http://dx.doi.org/10.1074/ jbc.M110.112045
28. Maehama T, Tanaka M, Nishina H, Murakami M, Kanaho Y, Hanada K. RalA functions as an indispensable signal mediator for the nutrient-sensing system. J Biol Chem 2008; 283:35053-9; PMID:18948269; http://dx.doi.org/10.1074/jbc. M805822200
29. Sato T, Nakashima A, Guo L, Tamanoi F. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J Biol Chem 2009; 284:12783-91; PMID:19299511; http://dx.doi.org/10.1074/jbc. M809207200
30. Uhlenbrock K, Weiwad M, Wetzker R, Fischer G, Wittinghofer A, Rubio I. Reassessment of the role of FKBP38 in the Rheb/mTORC1 pathway. FEBS Lett 2009; 583:965-70; PMID:19222999; http://dx.doi. org/10.1016/j.febslet.2009.02.015
31. Wang X, Fonseca BD, Tang H, Liu R, Elia A, Clemens MJ, et al. Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem 2008; 283:30482-92; PMID:18676370; http://dx.doi. org/10.1074/jbc.M803348200
32. Schmidt MV, Paez-Pereda M, Holsboer F, Hausch F. The prospect of FKBP51 as a drug target. ChemMedChem 2012; 7:1351-9; PMID:22581765; http://dx.doi.org/10.1002/cmdc.201200137
33. Kadeba PI, Vasauskas AA, Chen H, Wu S, Scammell JG, Cioffi DL. Regulation of store-operated calcium entry by FK506-binding immunophilins. Cell Calcium 2013; 53:275-85; PMID:23375350; http://dx.doi.org/10.1016/j.ceca.2012.12.008
34. Bouwmeester T, Bauch A, Ruffner H, Angrand P-O, Bergamini G, Croughton K, et al. A physical and functional map of the human TNF-α/NF-κ B signal transduction pathway. Nat Cell Biol 2004; 6:97-105; PMID:14743216; http://dx.doi.org/10.1038/ncb1086
35. Fabian A-K, März A, Neimanis S, Biondi RM, Kozany C, Hausch F. InterAKTions with FKBPs-mutational and pharmacological exploration. PLoS One 2013; 8:e57508; PMID:23469007; http://dx.doi.org/10.1371/journal.pone.0057508
36. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009; 16:259-66; PMID:19732725; http://dx.doi.org/10.1016/j.ccr. 2009.07.016
37. Hou J, Wang L. FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer. PLoS One 2012; 7:e36252; PMID:22590527; http://dx.doi.org/10.1371/journal. pone.0036252
38. Gopalakrishnan R, Kozany C, Gaali S, Kress C, Hoogeland B, Bracher A, et al. Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52. J Med Chem 2012; 55:4114-22; PMID:22455444; http://dx.doi.org/10.1021/jm201746x
39. Gopalakrishnan R, Kozany C, Wang Y, Schneider S, Hoogeland B, Bracher A, et al. Exploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52. J Med Chem 2012; 55:4123-31; PMID:22455398; http://dx.doi.org/10.1021/jm201747c
40. Wang Y, Kirschner A, Fabian AK, Gopalakrishnan R, Kress C, Hoogeland B, et al. Increasing the Efficiency of Ligands for FK506-Binding Protein 51 by Conformational Control. J Med Chem 2013; 56:3922-35; PMID:23647266; http://dx.doi. org/10.1021/jm400087k